Brief: Adaptive Biotechnologies Corp - Adaptive's Work With Epic Will Commence Immediately, With Clonoseq Integration Expected To Go Live In 2023
11/10/2022 13:10
Oct 11 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE ANNOUNCES PARTNERSHIP WITH EPIC TO INCREASE
ACCESS TO
MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN BLOOD CANCERS
* ADAPTIVE BIOTECHNOLOGIES CORP - ADAPTIVE'S WORK WITH EPIC
WILL
COMMENCE IMMEDIATELY, WITH CLONOSEQ INTEGRATION EXPECTED TO GO
LIVE IN 2023
Source text for Eikon: ID:nGNX65kh8z
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsAdvisory: Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary
Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates